Eric Schweibenz and Alexander Englehart wrote an article featured in the Intellectual Property Magazine-July issue, entitled "Intellectual Ventures v Aisin Seiki, et al"

In 2013, the U.S. enacted the Biologics Price Competition and Innovation Act ("BPCIA"), 42 U.S.C. § 262 to allow for abbreviated biologics license applications ("aBLA") to be filed for complex products which are biosimilar to/interchangeable with FDA-licensed biologics.

Todd Baker, Lisa Mandrusiak, Chris Riccuiti, and Michael Casey will be attending the 2020 PTAB Bar Association Annual Conference on March 10-12, 2020.

Eleven Oblon attorneys have been named to the 2020 edition of Best Lawyers in America.

Oblon's Patent Prosecution practice and partners from the firm's Chemical, Electrical & Mechanical and Litigation practices have received top national rankings in the 2019 edition of IAM Patent 1000: The World's Leading Patent Professionals.